Clinical Radiology
Volume 65, Issue 9 , Pages 677-684 , September 2010

Cardiac drugs used in cross-sectional cardiac imaging: what the radiologist needs to know

  • P. McParland

      Affiliations

    • Department of Cardiothoracic Radiology, Southampton University Hospitals NHS Trust, Southampton, UK
    • ,
  • E.D. Nicol

      Affiliations

    • Department of Radiology, Royal Brompton Hospital, London, UK
    • Department of Cardiology, Royal Brompton Hospital, London, UK
    • Department of Cardiology, Royal Berkshire Hospital, Reading, UK
    • ,
  • S.P. Harden

      Affiliations

    • Department of Cardiothoracic Radiology, Southampton University Hospitals NHS Trust, Southampton, UK
    • Corresponding Author InformationGuarantor and correspondent: S. P. Harden, Department of Cardiothoracic Radiology, Southampton University Hospitals NHS Trust, Southampton, UK. Tel.: +44 (0) 2380 794833; fax: +44 (0) 2380 796341.

Received 25 January 2010 ,Revised 28 March 2010 ,Accepted 6 April 2010.

References 

  1. Ropers D, Baum U, Pohle K, et al. Detection of coronary artery stenoses with thin-slice multi-detector row spiral computed tomography and multiplanar reconstruction. Circulation. 2003;107:664–666
  2. Srichai MB, Hecht EM, Kim D, et al. Dual-source computed tomography angiography image quality in patients with fast heart rates. J Cardiovasc Comput Tomogr. 2009;3:310–311
  3. American Society of Health System Pharmacists (ASHP) . American Hospital Formulary Service (AHFS) drug information. Bethesda, MD: American Society of Health System Pharmacists; 2004;pp. 1762–1770
  4. Nicol ED, Arcuri N, Rubens MB, et al. Considerations when introducing a new cardiac MDCT service. Avoiding the pitfalls. Clin Radiol. 2008;63:355–369
  5. Pannu HK, Alvarez W, Fishman EK. ß-blockers for cardiac CT: a primer for the radiologist. AJR Am J Roentgenol. 2006;186:S341–S345
  6. Roberts WT, Wright AR, Timmis JB, et al. Safety and efficacy of a rate control protocol for cardiac CT. Br J Radiol. 2009;82:267–271
  7. BNF Joint Formulary Committee . British National Formulary: BNF 57 2009. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain; 2009;pp. 89–90
  8. Brodde OE. Beta-1 and Beta-2 adrenoceptor polymerphisms: functional importance, impact on cardiovascular diseases and drug responses. Pharmacol Ther. 2008;117:1–29
  9. Kopp AF, Küttner A, Trabold T, et al. Multislice CT in cardiac and coronary angiography. Br J Radiol. 2004;77:S87–S97
  10. Tardif JC, Ford I, Tendera M, et al. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529–2536
  11. Dewey M, Hoffmann H, Hamm B. Multislice CT coronary angiography: effect of sublingual nitroglycerine on the diameter of coronary arteries. Rofo. 2006;178:600–604
  12. Decramer I, Vanhoenacker PK, Sarno G, et al. Effects of sublingual nitroglycerin on coronary lumen diameter and number of visualized septal branches on 64-MDCT angiography. AJR Am J Roentgenol. 2008;190:219–225
  13. Johnson PT, Eng J, Pannu HK, et al. 64-MDCT angiography of the coronary arteries: nationwide survey of patient preparation practice. AJR Am J Roentgenol. 2008;190:743–747
  14. Webb DJ, Muirhead GJ, Wulff M, et al. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25–31
  15. Wilson RF, Wyche K, Christensen BV, et al. Effects of adenosine on human coronary arterial circulation. Circulation. 1990;82:1595–1606
  16. Fenster MS, Feldman MD, Camarano G, et al. Correlation of adenosine thallium 201 perfusion patterns with markers for inducible ischaemia. Am Heart J. 1997;133:406–412
  17. Polad JE, Wilson LM. Myocardial infarction during adenosine stress test. Heart. 2002;87:e2
  18. Reyes E, Loong CY, Harbinson M, et al. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol. 2008;52:2008–2016
  19. Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol. 1994;23:384–389
  20. Wellnhoffer E, Olariu A, Klein C, et al. Magnetic resonance low-dose dobutamine test is superior to scar quantification for the prediction of functional recovery. Circulation. 2004;109:2172–2174
  21. Nagel E, Lehmkuhl HB, Bocksch W, et al. Non-invasive diagnosis of ischaemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999;99:763–770
  22. Wahl A, Paetsch I, Gollesch A, et al. Safety and feasibility of high-dose dobutamine–atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 2004;25:1230–1236
  23. Kuijpers D, Janssen CH, van Dijkman PR, et al. Dobutamine stress MRI. Part 1. Safety and feasibility of dobutamine cardiovascular magnetic resonance in patients suspected of myocardial ischemia. Eur Radiol. 2004;14:1823–1828
  24. Takase B, Nagata M, Kihara T, et al. Whole-heart dipyridamole stress first pass myocardial perfusion MRI for the detection of coronary artery disease. Jpn Heart J. 2004;45:475–486
  25. Bodi V, Sanchis J, Lopez-Lereu MP, et al. Prognostic value of dipyridamole stress cardiovascular magnetic resonance imaging in patients with known or suspected coronary artery disease. J Am Coll Cardiol. 2007;50:1174–1179
  26. BNF Joint Formulary Committee . British National Formulary: BNF 57 2009. London: British Medical Asosication and the Royal Pharmaceutical Society of Great Britain; 2009;p. 32

PII: S0009-9260(10)00151-0

doi: 10.1016/j.crad.2010.04.002

Clinical Radiology
Volume 65, Issue 9 , Pages 677-684 , September 2010

Article Tools

* Image Usage & Resolution